Literature DB >> 23743567

IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma.

Wen-Wei Sung1, Yao-Chen Wang, Po-Lin Lin, Ya-Wen Cheng, Chih-Yi Chen, Tzu-Chin Wu, Huei Lee.   

Abstract

PURPOSE: Interleukin-10 (IL-10) determines virus persistent infection and promotes viral-associated tumor progression via tumor immune escape. However, the role of IL-10 in tumor progression and prognosis in lung adenocarcinoma remains controversial. EXPERIMENTAL
DESIGN: To investigate how IL-10 is regulated by HPV E6, IL-10 promoter was constructed to understand which transcriptional factor could be responsible for its transcription. To verify which molecule could be responsible for IL-10-mediated soft agar growth and invasion capability, PCR array and mechanistic strategies were conducted. IL-10 and CIP2A mRNA levels in lung tumors from patients with lung cancer were determined by real-time reverse transcription PCR. The prognostic value of both molecules on survival was estimated by Cox regression model.
RESULTS: Mechanistic studies showed that IL-10 protein and mRNA expression was decreased in E6 knockdown TL1 cells and increased in E6- overexpressing TL4 cells. In addition, IL-10 transcription was predominantly regulated by E6-mediated phosphorylation of cAMP response element-binding protein (CREB) and C/enhancer-binding protein β (C/EBPβ) via phosphoinositide 3-kinase (PI3K) signaling pathway. IL-10-mediated tumor aggressiveness in vitro and in vivo occurs through increased CIP2A expression via PI3K signaling pathway. Among patients, IL-10 mRNA expression in lung tumors was positively correlated with CIP2A mRNA expression. Cox-regression analysis showed that IL-10 and CIP2A mRNA levels may independently predict survival in patients with lung adenocarcinoma, especially in patients with E6-positive tumors.
CONCLUSION: IL-10 production from lung tumors and immune cells promotes lung adenocarcinoma aggressiveness and patients with poor survival. We thus suggest that PI3K inhibitor combined with chemotherapy may potentially enhance tumor regression and improve patients' outcome and life quality. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743567     DOI: 10.1158/1078-0432.CCR-12-3439

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

Review 1.  Human papillomavirus and lung cancinogenesis: an overview.

Authors:  Antonio Carlos de Freitas; Ana Pavla Gurgel; Elyda Golçalves de Lima; Bianca de França São Marcos; Carolina Maria Medeiros do Amaral
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-29       Impact factor: 4.553

2.  Relationship between IL-10 expression and prognosis in patients with primary breast cancer.

Authors:  Ying Li; Ping Gao; Junlan Yang; Haiming Yu; Yanyun Zhu; Wen Si
Journal:  Tumour Biol       Date:  2014-08-17

3.  Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Authors:  Mads Duus Hjortsø; Stine Kiaer Larsen; Per Kongsted; Özcan Met; Thomas Mørch Frøsig; Gitte Holmen Andersen; Shamaila Munir Ahmad; Inge Marie Svane; Jürgen C Becker; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

4.  Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion.

Authors:  M P Ward; J P Spiers
Journal:  Br J Pharmacol       Date:  2017-04-07       Impact factor: 8.739

5.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

6.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

Review 7.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

8.  The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.

Authors:  Jau-Chung Hwang; Wen-Wei Sung; Hung-Pin Tu; Kun-Chou Hsieh; Chung-Min Yeh; Chih-Jung Chen; Hui-Chun Tai; Chao-Tien Hsu; Grace S Shieh; Jan-Gowth Chang; Kun-Tu Yeh; Ta-Chih Liu
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

9.  High Expression of MTA1 Predicts Unfavorable Survival in Patients With Oral Squamous Cell Carcinoma.

Authors:  Kuan-Yu Lin; Tzu-Cheng Su; Chung-Min Yeh; Wan-Ru Chao; Wen-Wei Sung
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

10.  Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Authors:  Chun-Yu Liu; Man-Hsin Hung; Duen-Shian Wang; Pei-Yi Chu; Jung-Chen Su; Tsung-Han Teng; Chun-Teng Huang; Ting-Ting Chao; Cheng-Yi Wang; Chung-Wai Shiau; Ling-Ming Tseng; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2014-09-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.